You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 637 INB-200: Phase I study of gene modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM) patients receiving maintenance temozolomide (TMZ): immunobiologic correlative data

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
637 INB-200: Phase I study of gene modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM) patients receiving maintenance temozolomide (TMZ): immunobiologic correlative data

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lamb L, Lobbous M, Goswami T, et al
637 INB-200: Phase I study of gene modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM) patients receiving maintenance temozolomide (TMZ): immunobiologic correlative data
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0637